Home | Publications | Treatments | Orthopaedic place holder
place holder place holder

Orthopaedic

The Dermatology Market Outlook to 2011


Publication Date   March 2007
Publisher   Business Insights
Product Type   Report
Pages   201
ISBN Number   not applicable
Product Code   RBI137
Ask a question about this product?

Price £1,495.00

approximately: $2,229 | €1,781

Summary


Introduction

The Dermatology Market Outlook to 2011 provides detailed analysis on 5 indications within the dermatology market, identifying high growth brands, future market leaders and key drug classes. The in-depth 6-year epidemiology and product sales forecasts in this report will enable you to plan effectively, evaluate changes in the competitive positions of leading companies and accurately benchmark your position.

Key findings of this new report

  • The psoriasis market is forecast to post the most aggressive growth rates over the period to 2011, as Raptiva and Daivobet drive growth over the forecast period. Psoriasis treatments are forecast to expand sales at a CAGR of 12.5%, reaching sales of $1.9bn in 2011.
  • With Roaccutane and Diane facing generic competition, the branded oral acne treatments market is set to decline over the forecast period. Forecast sales of the acne market are estimated at $2.7bn in 2011.
  • The corticosteroid market was valued at $2,783m in 2005, 5.8% up on year previous sales of $2,630m. Triple combination anti-infective/corticosteroid therapies are driving growth, whilst widespread genericization is restraining growth of the class as a whole.

The 5 Major dermatological indications covered are:

  • Acne
  • Psoriasis
  • Infectious diseases of the skin
  • Dermatitis
  • Rosacea

Your questions answered

  • What will be the major growth indications in the dermatology area over the period 2006-11?
  • How have recent major launches from companies such as Novartis, Astellas and Genentech performed?
  • Which companies will become the key players in the dermatology area over the period 2006-11?
  • Which products will be impacted by generic competitors over the period 2006-11?
  • What will the competitive landscape in acne, psoriasis, dermatitis, rosacea, viral, bacterial and fungal dermatological infections look like in 2011?

This report will enable you to...

  • Quantify patient potential, assess treatment trends and sales patterns with this report's in-depth coverage of the 5 major dermatological indications, the US, Japanese and top EU 5 markets and the top 10 leading companies.
  • Forecast sales of the major products in the dermatology area over the period 2006-11 in major dermatological indications, classes of treatments and by company.
  • Evaluate how market share of leading companies, such as Novartis, GlaxoSmithKline and Schering Plough, will change over the next 6 years, and assess your competitive position within the market.
  • Discover which indications have the greatest potential to provide franchise growth and understand the growth drivers of major classes of dermatological treatments including corticosteroids, anti-infectives, acne treatments and psoriasis treatments.

Content


  • Executive Summary
    • Patient potential
    • Global market analysis
    • Pipeline analysis
    • Competitive landscape
  • Chapter 1 Patient potential
    • Summary
    • Introduction
    • Acne
    • Overview
    • Diagnosis, treatment and management
    • Epidemiology
    • Forecast epidemiology
    • Psoriasis
    • Overview
    • Diagnosis, treatment and management
    • Epidemiology
    • Forecast epidemiology
    • Infectious diseases of the skin
    • Overview
    • Bacterial infections of the skin
    • Fungal infections of the skin
    • Viral infections of the skin
    • Diagnosis, treatment and management
    • Epidemiology
    • Viral skin infections
    • Fungal skin infections
    • Bacterial skin infections
    • Forecast epidemiology
    • Viral skin infections
    • Fungal skin infections
    • Bacterial skin infections
    • Dermatitis
    • Overview
    • Diagnosis, treatment and management
    • Epidemiology
    • Forecast epidemiology
    • Rosacea
    • Overview
    • Diagnosis, treatment and management
    • Epidemiology
    • Forecast epidemiology
  • Chapter 2 Global market analysis
    • Summary
    • Introduction
    • Market analysis by country
    • Licensing trends
    • Market analysis by drug class
    • Leading brands dynamics
    • Key events in the dermatology market
    • Continued approvals for biologic agents in the treatment of psoriasis
    • Black box warnings for Elidel and Protopic
    • Safety concerns over Roaccutane gain more traction
    • Acne treatments
    • Market analysis by drug class
    • Competitive dynamics of acne treatments
    • Leading acne treatment brands
    • Oral acne treatments market analysis
    • Market dynamics
    • Key brands analysis
    • Topical acne treatments market analysis
    • Market dynamics
    • Key brands analysis
    • Acne treatment sales forecasts to 2011
    • Psoriasis treatments
    • Market analysis by drug class
    • Competitive dynamics of psoriasis treatment classes
    • Leading brands of psoriasis treatments
    • Market dynamics
    • Key brands analysis
    • Psoriasis treatments sales forecasts to 2011
    • Corticosteroid treatments
    • Market analysis by drug class
    • Competitive dynamics of corticosteroid treatment classes
    • Leading brands of corticosteroid treatments
    • Corticosteroid treatments market analysis
    • Market dynamics
    • Key brands analysis
    • Corticosteroid treatment sales forecasts to 2011
    • Anti-infective treatments
    • Market analysis by drug class
    • Leading brands of anti-infective treatments
    • Market dynamics
    • Key brands analysis
    • Anti-infective treatment sales forecasts to 2011
    • Other dermatologic treatments
    • Leading brands of other dermatologic treatments
    • Key brands analysis
    • Other dermatologic treatment sales forecasts to 2011
    • Total Therapeutic market sales forecasts to 2011
  • Chapter 3 Pipeline analysis
    • Summary
    • Introduction
    • Key trends in R&D
    • New mechanism of action
    • Reformulations
    • Combination drugs
    • Biologics
    • The therapeutic area pipeline
    • Leading drugs in development
    • Profiles of key pipeline products
    • Phase II compounds
    • rambazole
    • Phase III compounds
    • Panaclar/BG-12
    • CNTO 1275 interleukin antagonist
    • Drugs in registration
    • Altabax (retapamulin)
    • Desonate (desonide)
    • Recently marketed drugs
    • Humira (adalimumab)
    • Oracea (doxycycline extended release sub anti-microbial dose)
    • Remicade (infliximab)
    • Taclonex (calcipotriene/betamethasone)
    • Ziana (clindamycin/tretinoin)
    • Pipeline forecasts
    • Factors affecting forecasts
    • Dermatology pipeline forecasts
  • Chapter 4 Competitive landscape
    • Summary
    • Introduction
    • Company market shares
    • Novartis
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
    • GlaxoSmithKline
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
    • Schering-Plough
    • Overview
    • Sales focus by drug class
    • Marketed Product Portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
    • Sanofi-Aventis
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
    • Johnson & Johnson
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
    • Bayer Schering Pharma
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
    • Stiefel Labs
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
    • Roche
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
    • Nestle/L'Oreal
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
  • Chapter 5 Appendix
    • IMS data
    • Index
  • List of Figures
    • Figure 1.1: Typical treatment patterns in the treatment of acne
    • Figure 1.2: Typical treatment patterns in the treatment of psoriasis
    • Figure 2.3: Global dermatology market share by geography, 2005
    • Figure 2.4: Sales of types of dermatology brands, 2004-5
    • Figure 2.5: Competitive dynamics of the global dermatology market by drug class, 2005
    • Figure 2.6: Competitive dynamics of the leading 10 brands in the global dermatology market, 2004-5
    • Figure 2.7: Competitive dynamics of subclasses in the acne treatments market, 2004-5
    • Figure 2.8: Competitive dynamics of the leading acne treatments in the global dermatology market, 2004-5
    • Figure 2.9: Competitive dynamics of the leading oral acne treatments in the global dermatology market, 2004-5
    • Figure 2.10: Competitive dynamics of the leading topical acne treatments in the global dermatology market, 2004-5
    • Figure 2.11: Competitive dynamics of classes in the psoriasis treatments market, 2004-5
    • Figure 2.12: Competitive dynamics of the leading psoriasis treatments in the global dermatology market, 2004-5
    • Figure 2.13: Competitive dynamics of classes in the corticosteroid treatments market, 2004-5
    • Figure 2.14: Competitive dynamics of the leading corticosteroid treatments in the global dermatology market, 2004-5
    • Figure 2.15: Competitive dynamics of subclasses in the anti-infective treatments market,
    • Figure 2.16: Competitive dynamics of the leading anti-infective treatments in the global dermatology market, 2004-5
    • Figure 2.17: Competitive dynamics of the leading other treatments in the global dermatology market, 2004-5
    • Figure 3.18: Prevailing R&D approaches, 2005
    • Figure 3.19: The dermatology pipeline by indication and stage of development, 2006
    • Figure 3.20: Leading recently launched products and late-stage R&D in the dermatology market, 2005
    • Figure 4.21: Competitive dynamics of the leading players in the global dermatology market,
    • Figure 4.22: Novartis' dermatology sales, 2005
    • Figure 4.23: GSK's dermatology sales by drug class, 2005
    • Figure 4.24: Schering-Plough's dermatology sales by drug class, 2005
    • Figure 4.25: Sanofi-Aventis' dermatology sales by drug class, 2005
    • Figure 4.26: J&J's dermatology sales by drug class, 2005
    • Figure 4.27: Schering AG's dermatology sales by drug class, 2005
    • Figure 4.28: Stiefel Labs' dermatology sales by drug class, 2005
    • Figure 4.29: Roche's dermatology sales by drug class, 2005
    • Figure 4.30: L'Oreal's dermatology sales by drug class, 2005
  • List of Tables
    • Table 1.1: Estimated prevalence of dermatological conditions in the seven major pharmaceutical markets, 2005
    • Table 1.2: Estimated prevalence of clinical acne across seven major markets, 2005
    • Table 1.3: Forecast epidemiology of clinical acne across the seven major markets, 2005-11
    • Table 1.4: Estimated prevalence of psoriasis across seven major markets, 2005
    • Table 1.5: Forecast epidemiology of psoriasis across the seven major markets, 2005-11
    • Table 1.6: Estimated prevalence of infectious diseases (viral) of the skin across seven major markets, 2005
    • Table 1.7: Estimated prevalence of infectious diseases (fungal) of the skin across seven major markets, 2005
    • Table 1.8: Estimated prevalence of infectious diseases (bacterial) of the skin across seven major markets, 2005
    • Table 1.9: Forecast epidemiology of infectious diseases (viral) of the skin across the seven major markets, 2005-11
    • Table 1.10: Forecast epidemiology of infectious diseases (fungal) of the skin across the seven major markets, 2005-11
    • Table 1.11: Forecast epidemiology of infectious diseases (bacterial) of the skin across the seven major markets, 2005-11
    • Table 1.12: Estimated prevalence of atopic dermatitis across seven major markets, 2005
    • Table 1.13: Forecast epidemiology of dermatitis across the seven major markets, 2005-11
    • Table 1.14: Estimated prevalence of rosacea across seven major markets, 2005
    • Table 1.15: Forecast epidemiology of rosacea across the seven major markets, 2005-11
    • Table 2.16: The global dermatology market by drug class, 2001-5
    • Table 2.17: Leading brands in the global dermatology market, 2004-5
    • Table 2.18: The global acne market by drug class, 2001-5
    • Table 2.19: Leading acne treatments in the global dermatology market,
    • Table 2.20: Leading oral acne treatments in the global dermatology market, 2004-5
    • Table 2.21: Leading topical acne treatments in the global dermatology market, 2004-5
    • Table 2.22: Acne treatments sales forecast, 2005-11
    • Table 2.23: The global psoriasis market by drug class, 2001-5
    • Table 2.24: Leading psoriasis treatments in the global dermatology market, 2004-5
    • Table 2.25: Psoriasis treatments sales forecast, 2005-11
    • Table 2.26: The global corticosteroid market by drug class, 2001-5
    • Table 2.27: Leading corticosteroid treatments in the global dermatology market, 2004-5
    • Table 2.28: Corticosteroid treatment sales forecast, 2005-11
    • Table 2.29: The global anti-infective market by drug class, 2001-5
    • Table 2.30: Leading anti-infective treatments in the global dermatology market, 2004-5
    • Table 2.31: Anti-infective treatment sales forecast, 2005-11
    • Table 2.32: Leading other treatments in the global dermatology market, 2004-5
    • Table 2.33: Other dermatologic treatment sales forecast, 2005-11
    • Table 2.34: Therapeutic sales forecasts by drug class, 2005-11
    • Table 3.35: Dermatology pipeline forecasts, 2005-11
    • Table 4.36: Leading players in the global dermatology market, 2004-5
    • Table 4.37: Novartis' dermatology product portfolio, 2004-5
    • Table 4.38: Novartis' dermatology R&D product pipeline, 2006
    • Table 4.39: GSK's dermatology product portfolio, 2004-5
    • Table 4.40: GSK's dermatology R&D product pipeline, 2006
    • Table 4.41: Schering-Plough's dermatology product portfolio, 2004-5
    • Table 4.42: Sanofi-Aventis' dermatology product portfolio, 2004-5
    • Table 4.43: Johnson & Johnson's dermatology product portfolio, 2004-5
    • Table 4.44: Johnson & Johnson's dermatology R&D product pipeline, 2006
    • Table 4.45: Schering AG's dermatology product portfolio, 2004-5
    • Table 4.46: Schering AG's dermatology R&D product pipeline, 2006
    • Table 4.47: Stiefel Lab's dermatology product portfolio, 2004-5
    • Table 4.48: Roche's dermatology product portfolio, 2004-5
    • Table 4.49: Roche's dermatology R&D product pipeline, 2006
    • Table 4.50: Nestle/L'Oreal's dermatology product portfolio, 2004-5